PL3896090T3 - Rozszczepialne proteolitycznie białko fuzyjne zawierające czynnik krzepnięcia krwi - Google Patents
Rozszczepialne proteolitycznie białko fuzyjne zawierające czynnik krzepnięcia krwiInfo
- Publication number
- PL3896090T3 PL3896090T3 PL21162926T PL21162926T PL3896090T3 PL 3896090 T3 PL3896090 T3 PL 3896090T3 PL 21162926 T PL21162926 T PL 21162926T PL 21162926 T PL21162926 T PL 21162926T PL 3896090 T3 PL3896090 T3 PL 3896090T3
- Authority
- PL
- Poland
- Prior art keywords
- fusion protein
- blood coagulation
- coagulation factor
- proteolytically cleavable
- cleavable fusion
- Prior art date
Links
- 102000015081 Blood Coagulation Factors Human genes 0.000 title 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 title 1
- 239000003114 blood coagulation factor Substances 0.000 title 1
- 229940019700 blood coagulation factors Drugs 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06012262A EP1867660A1 (en) | 2006-06-14 | 2006-06-14 | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
US81962006P | 2006-07-11 | 2006-07-11 | |
EP10168453.8A EP2256135B1 (en) | 2006-06-14 | 2007-06-14 | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP07726010.7A EP2032607B2 (en) | 2006-06-14 | 2007-06-14 | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP19162362.8A EP3564267B1 (en) | 2006-06-14 | 2007-06-14 | Proteolytically cleavable fusion proteins with high molar specific activity |
PCT/EP2007/005246 WO2007144173A1 (en) | 2006-06-14 | 2007-06-14 | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP21162926.6A EP3896090B1 (en) | 2006-06-14 | 2007-06-14 | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3896090T3 true PL3896090T3 (pl) | 2022-05-02 |
Family
ID=38430551
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07726010T PL2032607T5 (pl) | 2006-06-14 | 2007-06-14 | Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi |
PL21162926T PL3896090T3 (pl) | 2006-06-14 | 2007-06-14 | Rozszczepialne proteolitycznie białko fuzyjne zawierające czynnik krzepnięcia krwi |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07726010T PL2032607T5 (pl) | 2006-06-14 | 2007-06-14 | Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP3896090B1 (pl) |
JP (1) | JP5800458B2 (pl) |
KR (1) | KR101641899B1 (pl) |
AU (1) | AU2007260185B2 (pl) |
CA (1) | CA2655248C (pl) |
DK (2) | DK3896090T3 (pl) |
ES (2) | ES2889920T3 (pl) |
PL (2) | PL2032607T5 (pl) |
WO (1) | WO2007144173A1 (pl) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
EP2291523B1 (en) | 2008-06-24 | 2014-12-17 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
JP5936112B2 (ja) | 2009-02-11 | 2016-06-15 | アルブミディクス アクティーゼルスカブ | アルブミン変異体及び複合体 |
US20120148557A1 (en) * | 2009-08-20 | 2012-06-14 | Ulrich Kronthaler | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
US20120263701A1 (en) | 2009-08-24 | 2012-10-18 | Volker Schellenberger | Coagulation factor vii compositions and methods of making and using same |
CA2776241A1 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
JP5984676B2 (ja) | 2009-12-18 | 2016-09-06 | シーエスエル、リミテッド | ポリペプチドを精製する方法 |
EP2371857A1 (en) * | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
UA115120C2 (uk) * | 2010-07-09 | 2017-09-25 | Байоджен Хемофіліа Інк. | Спосіб застосування химерного поліпептиду фактора ix |
KR20140002601A (ko) | 2010-07-09 | 2014-01-08 | 바이오겐 이데크 헤모필리아 인코포레이티드 | 키메라 응고 인자 |
CN103732628B (zh) * | 2011-03-03 | 2017-06-23 | 酵活有限公司 | 多价杂多聚体骨架设计和构建体 |
US9597378B2 (en) * | 2011-10-06 | 2017-03-21 | Hanmi Science Co., Ltd. | Blood coagulation factor VII and VIIa derivatives, conjugates and complexes comprising the same, and use thereof |
EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
CN104271150A (zh) | 2012-01-12 | 2015-01-07 | 比奥根艾迪克Ma公司 | 嵌合因子viii多肽及其用途 |
PL2814502T3 (pl) | 2012-02-15 | 2018-02-28 | Csl Behring Gmbh | Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII |
EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
LT2814840T (lt) | 2012-02-15 | 2020-02-25 | Bioverativ Therapeutics Inc. | Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai |
EP3330283A3 (en) | 2012-03-16 | 2018-07-11 | Albumedix A/S | Albumin variants |
PT2882450T (pt) | 2012-07-11 | 2020-02-19 | Bioverativ Therapeutics Inc | Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo |
CN104768571B (zh) | 2012-07-13 | 2018-11-09 | 酵活有限公司 | 多价异多聚体支架设计和构建体 |
WO2014052490A1 (en) | 2012-09-25 | 2014-04-03 | Biogen Idec Ma Inc. | Methods of using fix polypeptides |
EP2917233A1 (en) | 2012-11-08 | 2015-09-16 | Novozymes Biopharma DK A/S | Albumin variants |
WO2014125082A1 (en) | 2013-02-16 | 2014-08-21 | Novozymes Biopharma Dk A/S | Pharmacokinetic animal model |
UY35463A (es) | 2013-03-15 | 2014-10-31 | Biogen Idec Inc | Formulaciones de polipéptido fc-factor ix. |
ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
EP3013359A4 (en) * | 2013-06-28 | 2017-01-25 | Biogen MA Inc. | Thrombin cleavable linker |
EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
DK4176894T3 (da) | 2014-01-10 | 2024-05-27 | Bioverativ Therapeutics Inc | Kimære faktor viii-proteiner og anvendelser deraf |
EP3164150B1 (en) | 2014-07-02 | 2020-11-04 | CSL Behring Lengnau AG | Modified von willebrand factor |
EP3298036B1 (en) | 2015-05-22 | 2022-04-06 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
RU2017145014A (ru) | 2015-05-22 | 2019-06-24 | Цсл Беринг Ленгнау Аг | Усеченные полипептиды фактора фон виллебранда для лечения гемофилии |
AU2016301303B2 (en) | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
WO2017029407A1 (en) | 2015-08-20 | 2017-02-23 | Albumedix A/S | Albumin variants and conjugates |
US20180340208A1 (en) * | 2015-10-15 | 2018-11-29 | Woods Hole Oceanographic Institution | Compositions and methods for absolute quantification of proteins |
RU2018128613A (ru) | 2016-01-07 | 2020-02-07 | Цсл Беринг Ленгнау Аг | Мутированный фактор фон виллебранда |
MX2018008337A (es) | 2016-01-07 | 2018-09-17 | CSL Behring Lengnau AG | Factor de von willebrand truncado mutado. |
TW201828974A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Csl貝林重組技能公司 | 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子(von Willebrand factor)多肽類 |
EP3538133B1 (en) | 2016-11-11 | 2021-02-17 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
AU2018264581B2 (en) * | 2017-05-11 | 2022-05-19 | Zentrum Für Forschungsförderung In Der Pädiatrie Gmbh | Concept for the treatment of monogenetic disorders |
MX2020003351A (es) | 2017-09-27 | 2020-10-12 | Sigilon Therapeutics Inc | Metodos, composiciones y elementos implantables que comprenden celulas activas. |
US20210145889A1 (en) | 2018-04-04 | 2021-05-20 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
TW202014181A (zh) | 2018-04-04 | 2020-04-16 | 美商希吉隆醫療公司 | 可植入顆粒及相關方法 |
AU2019270184A1 (en) | 2018-05-18 | 2020-11-26 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
KR20210141608A (ko) | 2019-03-19 | 2021-11-23 | 체에스엘 베링 렝나우 아게 | 치료요법에서 인자 ix 변이체 및 이의 용도 |
CN114072420B (zh) | 2019-07-04 | 2024-06-11 | 康诺贝林伦瑙有限公司 | 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf) |
WO2024081309A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
WO2024081310A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
GB8927722D0 (en) | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
WO1996001653A1 (en) * | 1994-07-11 | 1996-01-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
EP1276756A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
WO2002004598A2 (en) | 2000-07-12 | 2002-01-17 | Immunex Corporation | Improvement of cell culture performance by inhibitors of pyruvate dehydrogenase kinase |
PL374311A1 (pl) | 2001-12-21 | 2005-10-03 | Immunex Corporation | Sposób oczyszczania protein |
CA2475388A1 (en) | 2002-02-14 | 2003-08-21 | William J. Rutter | Chimeric molecules for cleavage in a treated host |
AU2003265866A1 (en) * | 2002-09-03 | 2004-03-29 | Vit Lauermann | Targeted release |
EP1444986A1 (en) * | 2003-02-07 | 2004-08-11 | Aventis Behring GmbH | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
EP1624891B2 (en) | 2003-05-06 | 2013-04-10 | Biogen Idec Hemophilia Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
CN1871252A (zh) | 2003-09-05 | 2006-11-29 | Gtc生物治疗学公司 | 在转基因哺乳动物奶中生产融合蛋白的方法 |
EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
-
2007
- 2007-06-14 KR KR1020097000784A patent/KR101641899B1/ko active IP Right Grant
- 2007-06-14 AU AU2007260185A patent/AU2007260185B2/en active Active
- 2007-06-14 EP EP21162926.6A patent/EP3896090B1/en active Active
- 2007-06-14 WO PCT/EP2007/005246 patent/WO2007144173A1/en active Application Filing
- 2007-06-14 ES ES19162362T patent/ES2889920T3/es active Active
- 2007-06-14 JP JP2009514703A patent/JP5800458B2/ja active Active
- 2007-06-14 DK DK21162926.6T patent/DK3896090T3/da active
- 2007-06-14 CA CA2655248A patent/CA2655248C/en active Active
- 2007-06-14 EP EP07726010.7A patent/EP2032607B2/en active Active
- 2007-06-14 ES ES21162926T patent/ES2910207T3/es active Active
- 2007-06-14 PL PL07726010T patent/PL2032607T5/pl unknown
- 2007-06-14 DK DK10168453.8T patent/DK2256135T3/da active
- 2007-06-14 PL PL21162926T patent/PL3896090T3/pl unknown
Also Published As
Publication number | Publication date |
---|---|
EP3896090A1 (en) | 2021-10-20 |
KR20090023486A (ko) | 2009-03-04 |
CA2655248A1 (en) | 2007-12-21 |
ES2910207T3 (es) | 2022-05-11 |
WO2007144173A1 (en) | 2007-12-21 |
JP5800458B2 (ja) | 2015-10-28 |
AU2007260185B2 (en) | 2013-01-31 |
EP2032607B1 (en) | 2014-01-22 |
JP2009539391A (ja) | 2009-11-19 |
EP2032607A1 (en) | 2009-03-11 |
DK3896090T3 (da) | 2022-03-21 |
CA2655248C (en) | 2016-02-09 |
PL2032607T3 (pl) | 2014-06-30 |
EP3896090B1 (en) | 2022-01-12 |
DK2256135T3 (da) | 2019-06-11 |
PL2032607T5 (pl) | 2017-10-31 |
EP2032607B2 (en) | 2017-02-22 |
ES2889920T3 (es) | 2022-01-14 |
KR101641899B1 (ko) | 2016-08-01 |
AU2007260185A1 (en) | 2007-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3896090T3 (pl) | Rozszczepialne proteolitycznie białko fuzyjne zawierające czynnik krzepnięcia krwi | |
DK2032607T3 (da) | Proteolytisk spalteligt fusionsprotein omfattende en blodkoaguleringsfaktor | |
ZA200901280B (en) | Exendin fusion proteins | |
IL196889A0 (en) | Albumin-insulin fusion proteins | |
IL222924A0 (en) | Albumin fusion proteins | |
IL197580A0 (en) | Albumin fusion proteins | |
PL1830872T3 (pl) | Białka fuzyjne | |
GB0426397D0 (en) | Fusion proteins | |
EP1988927A4 (en) | FUSIONS SYNTHETIC ANTIBODY-STRESS PROTEIN | |
ZA200810677B (en) | Fusion proteins, uses thereof and processes for producing same | |
EP1951862A4 (en) | CD40 LIGAND FUSION PROTEIN VACCINE | |
EP1934372A4 (en) | SSB-POLYMERASE HYBRID PROTEINS | |
IL189246A0 (en) | Albumin fusion proteins | |
IL197221A (en) | Method for cleaning up protein | |
EP1858546A4 (en) | MODIFIED TRANSFERRINFUSION PROTEINS | |
GB0519965D0 (en) | Joint fusion peg | |
WO2008033847A8 (en) | Modified protein polymers | |
EP2007884A4 (en) | ENZYMATIC FUSION PROTEINS AND THEIR USE | |
ATE412389T1 (de) | Chirurgisches system mit integrierten pneumatischen übergangsstücken | |
AP2777A (en) | Fixed-dose syringe with limited aspiration | |
ZA200801224B (en) | Albumin fusion proteins | |
IL186514A (en) | Purpose Protein Purification Methods | |
ZA200708576B (en) | Blood pressure lowering protein hydrolysates | |
GB0625681D0 (en) | A joint fixator | |
ZA200808656B (en) | Enzyme fusion proteins and their use |